Drug discovery targeting cell division proteins, microtubules and FtsZ

Area of Science:

• Drug discovery and development
• Cell biology
• Microbiology

Background:

• Eukaryotic cell division is a key target for anticancer drugs like paclitaxel and docetaxel.
• Drug resistance remains a significant challenge for existing microtubule-stabilizing agents (MSAs).
• Prokaryotic cell division, particularly the FtsZ protein, is an underexplored area for antibacterial drug discovery.

Purpose of the Study:

• To review research on novel anticancer agents targeting eukaryotic cell division.
• To explore the potential of targeting prokaryotic cell division protein FtsZ for new antibacterial drugs.
• To address the issue of drug resistance in both cancer and bacterial infections.

Main Methods:

• Review of existing literature on microtubule-stabilizing agents (MSAs).
• Analysis of research on bacterial cytokinesis and the FtsZ protein.
• Discussion of strategies to overcome drug resistance in anticancer and antibacterial therapies.

Main Results:

• Microtubule-stabilizing agents (MSAs) are crucial in anticancer drug discovery, but drug resistance is a major hurdle.
• The bacterial FtsZ protein presents a promising new target for developing next-generation antibacterial agents.
• Targeting FtsZ may help circumvent resistance to current antibiotics for infections like tuberculosis and MRSA.

Conclusions:

• Developing new-generation MSAs is essential to overcome drug resistance in cancer therapy.
• The FtsZ protein offers a significant opportunity for novel antibacterial drug discovery.
• Exploiting both eukaryotic and prokaryotic cell division pathways can lead to effective new therapies against resistant pathogens and cancers.